Yann Tessier

Acute Kidney Injury During Therapy With an Antisense Oligonucleotide Directed Against PCSK9

Eveline P. van Poelgeest, Reinout M. Swart, Michiel G.H. Betjes et al. · American Journal of Kidney Diseases · 2013 · 88 citations

Urology, Medicine, Kidney Failure +9

Antisense‐mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first‐in‐human randomized, placebo‐controlled trial

Eveline P. van Poelgeest, Michael R. Hodges, Matthijs Moerland et al. · British Journal of Clinical Pharmacology · 2015 · 87 citations · Full text

Assessing single-stranded oligonucleotide drug-induced effects in vitro reveals key risk factors for thrombocytopenia

Sabine Sewing, Adrian Roth, Michael Winter et al. · PLoS ONE · 2017 · 48 citations · Full text

Thrombopoiesis, Thrombosis, Venous Thrombosis +14

Establishment of a Predictive In Vitro Assay for Assessment of the Hepatotoxic Potential of Oligonucleotide Drugs

Sabine Sewing, Franziska Boess, Annie Moisan et al. · PLoS ONE · 2016 · 36 citations · Full text

Immunology, Pathology, Oxidative Stress +26

Inhibition of EGF Uptake by Nephrotoxic Antisense Drugs In Vitro and Implications for Preclinical Safety Profiling

Annie Moisan, Marcel Gubler, Jitao David Zhang et al. · Molecular Therapy — Nucleic Acids · 2016 · 33 citations · Full text

Urology, Nephrotoxic Antisense Drugs, Preclinical Drug Evaluation +15